CoChat

Combined vitamin B6-magnesium treatment in autism spectrum disorder

Open access
Nye, Chad, Brice, Alejandro · 2005 · Cochrane Database of Systematic Reviews
Cited by 150

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The use of mega-vitamin intervention began in the 1950s with the treatment of schizophrenic patients. Pyroxidine (vitamin B6) was first used with children diagnosed with "autism syndrome" when speech and language improvement was observed in some children as a result of large doses of B6. A number of studies attempted to assess the effects of vitamin B6-Magnesium (Mg) was found to reduce undesirable side effects from B6) on characteristics such as verbal communication, non-verbal communication, interpersonal skills, and physiological function, in individuals with autism. OBJECTIVES: To determine the efficacy of vitamin B6 and magnesium (B6-Mg) for treating social, communication, and behavioural responses of children and adults with autism. SEARCH STRATEGY: We searched the Cochrane Controlled Trials Register (Cochrane Library, Issue 2, 2002), MEDLINE (1966 to January 2002), EMBASE (1980 to January 2002), PsycINFO (1887 to January 2002), Dissertation Abstracts International (1861 to January 2002). The search engine FirstSearch was also used (January 2002). All searches were updated in April 2005. Reference lists for all the obtained studies and other review articles were examined for additional studies. SELECTION CRITERIA: All studies in which the participants had been diagnosed with autistic spectrum disorder were randomly allocated prior to intervention and in which outcomes were compared to either a placebo or non-treated group were included. DATA COLLECTION AND ANALYSIS: Two reviewers independently evaluated and extracted data from all potential studies identified for inclusion. MAIN RESULTS: This update includes a new trial (Kuriyama 2002) to bring the total of included studies to three (total n=33). One study, which used a cross-over design (Tolbert 1993) provided insufficient data to conduct an analysis. Another crossover study (Findling 1997) yielded no significant differences between treatment and placebo group performances following the B6 intervention on measures of social interaction, communication, compulsivity, impulsivity, or hyperactivity. The latest study (Kuriyama 2002) was motivated by evidence from epilepsy research and was focussed on a subgroup of children with pervasive developmental disorders (PDDs) who exhibited clinical features similar to those with pyroxidine-dependent epilepsy. This small study (n=8) only measured IQ and 'Social Quotient' and found a statistically significant benefit for IQ (5.2, 95% CI = [0.2 to 10.3]) when in the treated group, by using change scores. AUTHORS' CONCLUSIONS: Due to the small number of studies, the methodological quality of studies, and small sample sizes, no recommendation can be advanced regarding the use of B6-Mg as a treatment for autism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd003497.pub2

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 36

  1. Findling, 1997, High-dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutary effects in a double-blind, placebo-controlled study, Journal of Autism and Developmental Disabilities, 27, 467, 10.1023/A:1025861522935 · DOI
  2. Kuriyama, 2002, Pyridoxine treatment in a subgroup of children with pervasive developmental disorders, Developmental Medicine & Child Neurology, 44, 283, 10.1017/S0012162201232071 · DOI
  3. Tolbert, 1993, Brief report: Lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium, Journal of Autism and Developmental Disabilities, 23, 193, 10.1007/BF01066428 · DOI
  4. Barthelemy, 1980, Biological and clinical effects of oral magnesium and associated magnesium-vitamin B6 administration on certain disorders observed in infantile autism (author's transl), Therapie, 35, 627
  5. Barthelemey, 1981, Behavioral and biological effects of oral magnesium, vitamin B6, and combined magnesium-B6 administration in autistic children, Magnesium Bulletin, 2, 150
  6. Barthelemy, 1983, Value of behavior scales and urinary homovanillic acid determinations in monitoring the combined treatment with vitamim B6 and magnesium of children displaying autistic behavior, Neuropsychiatrie de l Enfance et de l'Adolescence, 31, 289
  7. Barthelemy, 1985, Marqueurs cliniques (items d'echelles de comportement), electrophysiologiques (potentials evoques conditionnes) et biochimiques (acide homovanillique urinaire) dans l'autisme de l'enfant, L'Encephale, 11, 101
  8. Bonish, 1968, Experiences with pyrithioxin in brain-damaged children with autistic syndrome, Praxis der Kinderpsychologie und Kinderpsychiatrie., 17, 308
  9. Jonas, 1984, Clinical and biochemical value of Magnesium + vitamin B6 combination in the treatment of residual autism in adults, Therapie, 39, 661
  10. Lelord, 1978, L'acide homovanilique urinaire et ses modifications par ingestion de vitamine B6: Exploration fonctionnelle dans l'autisme de l'enfant? Rev. Neurol (Paris) 1978;134(12):797-801.Lelord G, Muh JP, Barthelemy C, Martineau J, Garreau J. Effects of pyridoxine and magnesium on autistic symptoms-initial observations, Rev. Neurol (Paris), 134, 797
  11. Lelord, 1981, Effects of pyridoxine and magnesium on autistic symptoms-initial observations, Journal of Autism and Developmental Disabilities, 11, 219, 10.1007/BF01531686 · DOI
  12. Lelord, 1982, Clinical and biological effects of high doses of vitamin B6 and Magnesium on autistic children, Acta Vitaminologica et Enzymologica, 4, 27
  13. Martineau, 1981, Effects of vitamin B6 on averaged evoked potentials in infantile autism, Biological Psychiatry, 16, 627
  14. Martineau, 1982, Comparative effects of oral B6 Mg and Mg administration on evoked potentials conditioning in autistic children, 411
  15. Martineau, 1985, Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism, Biological Psychiatry, 20, 467, 10.1016/0006-3223(85)90019-8 · DOI
  16. Martineau, 1988, Brief Report: An open middle-term study of combined vitamin B6-Magnesium in a subgroup of autistic children selected on their sensitivity to this treatment, Journal of Autism and Developmental Disorders, 18, 435, 10.1007/BF02212198 · DOI
  17. Martineau, 1989, Electrophysiological effects of fenfluramine or combined vitamin B6 and magnesium on children with autistic behaviour, Developmental Medicine & Child Neurology, 31, 721, 10.1111/j.1469-8749.1989.tb04067.x · DOI
  18. Menage, 1992, CD4+ CD45RA+ T lymphocyte deficiency in autistic children: effect of a pyridoxine-magnesium treatment, Brain Dysfunction, 5, 326
  19. Rimland, 1978, The effect of high doses of Vitamin B6 on autistic children: a double-blind crossover study, American Journal of Psychiatry, 135, 472, 10.1176/ajp.135.4.472 · DOI · Paper page
  20. Alderson, 2004, Cochrane Reviewers' Handbook 4.2.2 (updated December 2003). In: The Cochrane Library, Issue 1, 2004
  21. Ananth, 1973, Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics, Canadian Psychiatric Association Journal, 18, 377, 10.1177/070674377301800505 · doi:10.1177/070674377301800505
  22. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
  23. Bucci, 1973, Pyridoxine and schizophrenia, British Journal of Psychiatry, 122, 240, 10.1192/bjp.122.2.240 · doi:10.1192/bjp.122.2.240
  24. Campbell, 1985, Behavioral and cognitive measures used in psychopharamocologic studies of infantile autism, Psychopharamacology Bulletin, 21, 1047
  25. DiLalla, 1994, Domains of the Childhood Autism Rating Scale; Relevance for diagnosis and treatment, Journal of Autism and Developmental Disorders, 24, 115, 10.1007/BF02172092 · DOI
  26. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  27. Freeman, 1986, A scale for rating symptoms of patients with the syndrome of autism in real life settings, Journal of the American Academy of Child Psychiatry, 25, 130, 10.1016/S0002-7138(09)60610-5 · DOI
  28. Goyette, 1978, Normative data on revised Conners parent and teacher rating scales, Journal of Abnormal Child Psychology, 6, 221, 10.1007/BF00919127 · DOI · Paper page
  29. Greenberg, 1970, An evaluation of niacinamide in the treatment of childhood schizophrenia, American Journal of Psychiatry, 127, 89, 10.1176/ajp.127.1.89 · DOI · Paper page
  30. Insel, 1983, Obsessive-compulsive disorder: A double-blind trial of clomipramine and clorgyline, Archives of General Psychiatry, 40, 605, 10.1001/archpsyc.1983.04390010015002 · DOI · Paper page
  31. National Institutes of Mental Health, 1985, Clinical Global Impression Scale, Psychopharamacology Bulletin, 21, 839
  32. Overall, 1988, Behavioral assessment of psychopathology in children: Infantile autism, Journal of Clinical Psychology, 44, 708, 10.1002/1097-4679(198809)44:5<708::AID-JCLP2270440507>3.0.CO;2-T · DOI · Paper page
  33. Pfeiffer, 1996, Efficacy of vitamin B6 and magnesium in the treatment of autism: A methodology review and summary of outcomes, Journal of Autism and Developmental Disorders, 25, 481, 10.1007/BF02178295 · DOI
  34. Rimland, 1964, Infantile autism: The syndrome and its implications for neural theory of behavior
  35. Rimland, 1973, High-doseage levels of certain vitamins in the treatment of children with mental disorders
  36. Schaumberg, 1983, Sensory neuropathy from pyridoxine abuse, New England Journal of Medicine, 309, 445, 10.1056/NEJM198308253090801 · DOI · Paper page

Cited by

Metadata

Authors
Nye, C., & Brice, A.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2005-10-19
Volume
2009
Issue
1
Pages
CD003497-CD003497
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1746011489
Cited by
150
References
3
FWCI
3.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.